BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-6 out of 6 found
  Current Search:  stargardt: 6     

HTML
100%
Rodman & Renshaw Annual Global Investment Conference Presenter Profiles
NEW YORK --(Business Wire)-- The Rodman & Renshaw Annual Global Investment Conference takes place November 10, 2008 - November 12, 2008 at the New York Palace Hotel in New York.

Listed below are the Rodman & Renshaw Annual...

TMC Net:  Nov 13 2008 2:54AM
Matching: stargardt
Find similar documents
HTML
100%
Rodman & Renshaw Annual Global Investment Conference Presenter Profiles
NEW YORK --(Business Wire)-- The Rodman & Renshaw Annual Global Investment Conference takes place November 10, 2008 - November 12, 2008 at the New York Palace Hotel in New York.

Listed below are the Rodman & Renshaw Annual...

TMC Net:  Nov 10 2008 10:43PM
Matching: stargardt
Find similar documents
HTML
100%
Acucela to Present at the Rodman & Renshaw Healthcare Conference
- Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for blinding eye diseases, announced today that Ryo Kubota, M.D., Ph.D., Acucela's chief executive officer, will present a company update at the Rodman ...
Pharma Live:  Nov 8 2008 1:22AM
Matching: stargardt
Find similar documents
HTML
100%
Management of Retinitis Pigmentosa
ELIOT L.

BERSON, MD Retinitis pigmentosa (RP) has a prevalence of about 1 in 4000; an estimated 2 million people are affected worldwide.

The condition is most often inherited by an autosomal dominant, autosomal recessive, or X-linked...

Retinal Physician:  Oct 30 2008 10:18AM
Matching: stargardt
Find similar documents
HTML
100%
Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degen
BOTHELL, Wash.

& TOKYO--(BUSINESS WIRE)--Acucela Inc.

and Otsuka Pharmaceutical Co., Ltd.

announced today that they have entered into a definitive agreement to co-develop Acucelas lead compound ACU-4429 which is currently in...

Business Wire via Yahoo!:  Sep 4 2008 7:18AM
Matching: stargardt
Find similar documents
HTML
100%
Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry
BOTHELL, Wash.

& TOKYO--(BUSINESS WIRE)--Acucela Inc.

and Otsuka Pharmaceutical Co., Ltd.

today announced that they have entered into a definitive agreement to co-develop Rebamipide ophthalmic suspension (hereinafter,...

Business Wire via Yahoo!:  Sep 4 2008 7:07AM
Matching: stargardt
Find similar documents

  Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997- - BioPortfolio Limited.